PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016, 105: 136-144. PMID: 27521616, PMCID: PMC5072177, DOI: 10.1016/j.biomaterials.2016.07.037.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryGlioblastoma multiformeChemotherapeutic drugsFirst-line treatmentExtracranial solid tumorTumor-bearing animalsSurvival of animalsBrain extracellular spaceLine treatmentTumor bedIntracranial tumorsOrthotopic modelTreatment resistanceSolid tumorsGBM treatmentTherapeutic efficacyNew treatmentsTumor tissueHealthy animalsGBM prognosisFree gemcitabineMR contrast agentsNucleoside analoguesDrugsGemcitabineSuccess and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions
Corso CD, Bindra RS. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars In Radiation Oncology 2016, 26: 281-298. PMID: 27619250, DOI: 10.1016/j.semradonc.2016.06.003.Peer-Reviewed Original ResearchConceptsCurrent standard treatmentGlioblastoma multiformeStandard treatmentTreatment of GBMDistant brain relapseAggressive intracranial tumorBrain relapseAggressive therapyModality therapySurgical resectionCombined modalityIntracranial tumorsModality approachOncology communityTherapyMultiformeTreatmentUnanswered questionsImmunotherapyResectionRelapseFailureTumors